Thrombomodulin as a new marker of endothelial dysfunction in chronic kidney disease in children by Drożdż, Dorota et al.
Research Article
Thrombomodulin as a New Marker of Endothelial Dysfunction in
Chronic Kidney Disease in Children
Dorota Drożdż ,1 Monika Łątka ,1 Tomasz Drożdż ,2 Krystyna Sztefko,3
and Przemko Kwinta 4
1Department of Pediatric Nephrology and Hypertension, Jagiellonian University Medical College, 265 Wielicka St.,
30-663 Krakow, Poland
21st Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College,
17 Kopernika St., 31-501 Krakow, Poland
3Department of Clinical Biochemistry, Jagiellonian University Medical College, 265 Wielicka St., 30-663 Krakow, Poland
4Department of Pediatrics, Jagiellonian University Medical College, 265 Wielicka St., 30-663 Krakow, Poland
Correspondence should be addressed to Dorota Drożdż; dadrozdz@cm-uj.krakow.pl
Received 7 September 2017; Revised 4 December 2017; Accepted 24 December 2017; Published 28 February 2018
Academic Editor: Grazyna Kwapiszewska
Copyright © 2018 Dorota Drożdż et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Endothelial dysfunction (ED) and oxidative stress are potential new pathomechanisms of cardiovascular diseases in patients with
chronic kidney disease (CKD). The aim of the study was to assess the association between endothelial dysfunction, oxidative stress
biomarkers, and cardiovascular risk factors in children with CKD. Serum oxidized LDL (oxLDL), protein carbonyl group, urea,
creatinine, cystatin C, thrombomodulin, asymmetric dimethylarginine (ADMA), von Willebrand factor, brain natriuretic
peptide (BNP), lipids, high sensitivity C-reactive protein, intercellular adhesion molecule-1 levels, and albuminuria were
measured. Anthropometric, ambulatory blood pressure (BP) measurements and echocardiography were performed. The studied
group consisted of 59 patients aged 0.7–18.6 (mean 11.1) years with stages 1 to 5 CKD. Thrombomodulin strongly correlated
with creatinine (R = 0 666; p < 0 001), cystatin C (R = 0 738; p < 0 001), BNP (R = 0 406; p = 0 001), ADMA (R = 0 353; p = 0 01),
oxLDL (R = 0 340; p = 0 009), 24-hour systolic (R = 0 345; p = 0 011) and mean (R = 0 315; p < 0 05) BP values, and left
ventricular mass index (LVMI, R = 0 293; p = 0 024) and negatively with estimated glomerular filtration rate (R = −0 716;
p < 0 001). In children with CKD, TM strongly depended on kidney function parameters, oxLDL levels, and 24-hour systolic
and mean BP values. Thrombomodulin seems to be a valuable marker of ED in CKD patients, correlating with CKD stage as
well as oxidative stress, BP values, and LVMI.
1. Introduction
Cardiovascular diseases are the most frequent cause of mor-
bidity and mortality in patients with chronic kidney disease
(CKD). The adult population with impaired renal function
is characterized by high incidence of classical cardiovascular
risk factors; however, this cannot explain the high prevalence
of cardiovascular events in children with kidney function
impairment. Therefore, other factors such as endothelial
dysfunction (ED) and oxidative stress are considered.
Initially, ED was studied in the most advanced stage of
CKD (dialyzed patients) and a reduction in endothelial-
dependent vasodilatation of the brachial artery was demon-
strated. Recent studies supported the concept that ED is pres-
ent at early stages of chronic kidney disease [1, 2].
Endothelial cells play a key role in maintaining vascu-
lar homeostasis. They regulate vasodilatation, fibrinolysis,
and thrombosis through the synthesis and release of
substances such as nitric oxide, prostacyclin, thrombomod-
ulin, and tissue plasminogen activator [3, 4]. Endothelial
damage results in reduced release of protective substances
and at the same time increased release of counteractive
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substances—endothelin I, angiotensin II, plasminogen acti-
vator inhibitor-1 (PAI-1), and von Willebrand factor
(vWF), leading to vasoconstriction, platelet activation,
and prothrombotic and antifibrinolytic activity.
Noninvasive methods for ED assessment include evalua-
tion of shed endothelial surface layer components—soluble
thrombomodulin (TM) and syndecan-1 [5]. TM is a
transmembrane glycoprotein built from 5 domains. Its
anticoagulant effect is mediated by the binding of thrombin
and activation of protein C. Active protein C inhibits the
coagulation cascade through degradation of active factors V
and VIII and inactivation of tissue plasminogen activator
inhibitor. Thrombomodulin has also anti-inflammatory
activity. In the case of endothelial cell damage, its transmem-
brane portion is released and may be identified as a soluble
TM (sTM) and the TM molecule loses its vasoprotective
properties [6].
Asymmetric dimethylarginine (ADMA), an endogenous
inhibitor of nitric oxide synthetase, is the recognized
mediator of endothelial injury [7]. Intravenous infusion
of small doses of ADMA resulted in an increase of sys-
temic vascular resistance and mean blood pressure in
healthy volunteers [8]. Clinical trials have shown that
ADMA is not only a risk factor for cardiovascular death
and cardiovascular events but also progression of renal
failure in patients with CKD [9, 10].
Another endothelial injury marker is the von Willebrand
factor, a glycoprotein produced by endothelial cells and
megakaryocytes. vWF is a cofactor of thrombocyte adhesion
to connective tissue collagen, thereby exerting prothrombotic
action. In the ASCOT study, patients with hypertension (HT)
and organ damage (OD) had significantly higher vWF
concentrations than those with HT but without OD (137 ver-
sus 125 IU/dl). After 6 months of intensive treatment, there
was a reduction in systolic blood pressure and a decrease in
vWF concentration suggesting an improvement in endothe-
lial function [11].
Increased urinary albumin excretion is not only a symp-
tom of kidney disease but also an exponent of generalized
endothelial dysfunction and cardiovascular risk. Because of
technical difficulties in obtaining daily urine collection,
the albumin to creatinine ratio in the first urine volume
is increasingly used in clinical trials. In the study con-
ducted in Denmark by Borch-Johnsen et al., microalbumi-
nuria (>0.65mg/mmol) significantly increased the risk of
ischemic heart disease regardless of other atherosclerosis
risk factors [12].
In patients with CKD, both increased reactive oxygen
(ROS) and nitrogen radical (RNS) generation and decreased
antioxidative potential have been shown [13–15]. Low-
density lipoprotein particles modified in the process of oxida-
tion (oxLDLs) develop atherogenic properties and become
cytotoxic to vascular endothelial cells, stimulating smooth
muscle growth and macrophage attraction. OxLDLs also
inhibit macrophage mobility resulting in their accumulation
and formation of fatty streaks—the initial stage of the athero-
sclerotic process [16].
The aim of the study was to assess the association
between endothelial dysfunction and oxidative stress
biomarkers and cardiovascular risk factors in children with
chronic kidney disease.
2. Materials and Methods
The prospective study was conducted between June 2008 and
February 2011. The study was performed in accordance with
the Declaration of Helsinki of 1975 for Human Research and
approved by the Bioethical Committee (KBET/17/B/2006).
The parents and patients were educated as to the objective
and method of performing the study and gave their written
informed consent.
2.1. Subjects. Patients aged 0–18 years with diagnosed
chronic kidney disease and elevated thrombomodulin level
(>5ng/ml) were included.
The exclusion criteria were lack of consent of the patient
or parents, congenital heart defects or other primary heart
diseases, acute infections during measurements, acute dam-
age, or failure of other organs.
2.2. Blood Sampling and Biochemical Analysis. Blood samples
for basic research were taken on routine admission for
diagnostic check-up in all patients (fasting for 12 hours).
Additionally, three samples (for clot, EDTA, and citrate)
were collected and centrifuged and plasma and serum were
frozen at −80°C. Biochemical analyses were performed, and
urea, creatinine, cystatin C, TM, ADMA, brain natriuretic
peptide (BNP), vWF, fibrinogen, and lipids were measured.
Based on serum creatinine, estimated glomerular filtration
rate (eGFR) with the Schwartz et al. [17] and Filler et al.
[18] formulas was calculated. Patients were divided into
groups depending on CKD stage [group 1: CKD stages 1
+ 2 (GFR> 60); group 2: CKD stage 3 (GFR=30–59);
group 3: CKD stage 4 (GFR=15–29ml/min/1.73m2);
group 4: dialyzed children].
To assess endothelial dysfunction and oxidative stress,
the concentration of TM, ADMA, vWF, and oxLDL particles
and the concentration of carbonyl groups resulting from
oxidation of proteins were used. Concentrations of serum
thrombomodulin (American Diagnostica Inc., USA), high
sensitive C-reactive protein (hsCRP) (R&D Systems, USA),
oxLDL (Mercodia Inc., Sweden), protein carbonyl groups
(Cayman Chemical Company, USA), intercellular adhesion
molecule-1 (ICAM-1) (R&D Systems, USA), and vWF activ-
ity (Diagnostica Stago, France) were determined with ELISA.
BNP concentrations were measured with the IRMA method
(Cis Bio International, France).
2.3. Anthropometric and Blood Pressure Measurements.
Anthropometric measurements of patients such as weight,
height, and waist circumference were measured during each
visit, and body mass index (BMI) was calculated. Ambulatory
blood pressure measurements (ABPM) with SpaceLabs
90207 device and cuff of appropriate size were performed.
Blood pressure (BP) measurements were performed every
20 minutes during the day and every 30 minutes during the
night. Mean values of systolic (SBP), diastolic (DBP), and
mean BP (mean arterial pressure—MAP) were calculated.
Hypertension was defined as BP values equal to or exceeding
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the 95th percentile for gender, age, and height. BP values
were analyzed and expressed in standard deviations (SD).
2.4. Echocardiography. Echocardiographic examinations
were performed by an experienced cardiologist using HP
5500 unit with S4 and S8 variable frequency probes. In
children on chronic hemodialysis, echocardiography was
performed on the day between two hemodialysis procedures,
while in children on peritoneal dialysis, it was performed
during the daily exchange, with a low volume of dialysate
in the peritoneal cavity. LV mass (LVM) was calculated by
the formula described by Devereux and Reichek [19]. LVM
index (LVMI) was obtained by dividing LVM by height2.7
to normalize and linearize the relationship between LVM
and height [20].
2.5. Statistical Analysis. Qualitative values were compared by
the chi-square test. Because data of the majority of variables
did not show normal distribution, they are presented as
median [25th–75th percentile]. Differences between the
groups were compared using the Mann–Whitney U test.
Spearman’s rank correlation was used to relate endothelial
dysfunction and oxidative stress markers. Statistical calcula-
tions were performed using a commercially available statisti-
cal package (Statistica PL). A value of p < 0 05was considered
significant in all statistical analyses.
3. Results
We examined 59 patients (36 boys and 23 girls) aged 0.7 to
18.6 (mean 11.1) years with stages 1 to 5 CKD (7 in stages
1 and 2, 15 in stage 3, 15 in stage 4, and 22 in stage 5) who
were under constant medical control in the University
Children’s Hospital in Krakow. Among diseases leading to
the development of CKD in the examined children, the high-
est prevalence was noted in congenital abnormalities of the
kidney and urinary tract (59%) and nephrotic syndrome.
Patients were divided into 2 groups based on the throm-
bomodulin concentration. A cut-off point of double upper
limit of normal (ULN) for elevated thrombomodulin was
proposed. Clinical data and basic kidney function parameters
depending on thrombomodulin concentration are presented
in Table 1.
There were no significant differences in cholesterol con-
centrations between children with high and low thrombo-
modulin (Table 2). Patients with high TM levels had
significantly higher ADMA (1.23 (0.90; 1.40) versus 0.94
(0.75; 1.16) μmol/l; p < 0 05), BNP (15.63 (5.88; 24.23) versus
4.43 (1.00; 15.39); p < 0 05), and oxLDL (88.6 (78.7; 106.9)
versus 80.6 (67.4; 91.9); p < 0 05) concentrations. The con-
centrations of vWF, carbonyl groups, hsCRP, ICAM-1, and
fibrinogen did not vary significantly (Table 3). Furthermore,
they had elevated blood pressure values in 24-hour measure-
ments: systolic (118.0 (113.0; 126) versus 113.0 (105.0; 118.0);
Table 1: Basic clinical data and kidney function parameters depending on thrombomodulin concertation in the investigated group of 59
patients.
Parameter
Thrombomodulin
p value∗<2xULN (n = 26) ≥2xULN (n = 33)
Age (years) 10.5 (5.0; 16.0) 12.1 (9.1; 15.3) 0.277
Male sex (n) 17 (65.4%) 19 (57.5%) 0.599
Height (z-score) −0.35 (−1.77; 0.07) −1.34 (−2.38; −0.27) 0.097
Body mass (z-score) −0.84 (1.30; 0.11) −1.06 (−2.55; −0.01) 0.320
BMI (kg/m2) 16.5 (15.8; 18.6) 16.8 (14.9; 20.1) 0.970
BMI (z-score) −0.62 (−1.11; 0.53) −0.66 (−1.45; 0.44) 0.903
Creatinine (μmol/l) 110.8 (93.8; 179.3) 403.0 (283.3; 725.3) <0.001
Cystatin (mg/l) 1.58 (1.25; 2.06) 4.21 (3.05; 5.82) <0.001
eGFR Filler (ml/min/1.73m2) 55.2 (38.8; 72.0) 18.4 (12.0; 26.2) <0.001
Microalbuminuria (mg/l) 18.0 (10,7; 63.0) 99.5 (24.5; 423.0) 0.005
Values presented as median (25th–75th percentile). ∗Mann–Whitney U test. ULN: upper limit of normal; BMI: body mass index; eGFR: estimated glomerular
filtration rate.
Table 2: Cholesterol concentrations depending on thrombomodulin concentration in the investigated group of 59 patients.
Parameter
Thrombomodulin
p value∗<2xULN (n = 26) ≥2xULN (n = 33)
Total cholesterol (mmol/l) 4.62 (4.13; 5.12) 4.96 (4.15; 6.04) 0.465
TGL (mmol/l) 1.47 (1.23; 2.09) 1.60 (1.25; 2.82) 0.769
HDL (mmol/l) 1.27 (1.12; 1.56) 1.19 (1.03; 1.61) 0.500
LDL (mmol/l) 2.59 (2.30; 2.91) 2.31 (2.01; 3.29) 0.975
Values presented as median (25th–75th percentile). ∗Mann–Whitney U test. ULN: upper limit of normal; TGL: triglycerides; HDL: high-density lipoprotein;
LDL: low-density lipoprotein.
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p = 0 012) and MAP (87.0 (78.0; 92.0) versus 82.0 (77.0;
88.0); p = 0 022). There were no differences in other BP
values (Table 4). There were no significant differences in
thrombomodulin concentrations based on albuminuria
groups (see Figure 1).
Thrombomodulin concentrations increased with CKD
stage (7.82 versus 9.30 versus 10.44 versus 15.25 ng/ml;
p < 0 001), respectively, as shown in Figure 2. There were
significant differences in median thrombomodulin concen-
tration between CKD stages 1+ 2, 3, 4, and 5 (p < 0 001;
p < 0 001; p = 0 003).
There was a significant correlation between thrombo-
modulin concentration and markers of renal function—urea
(R = 0 522; p < 0 001), creatinine (R = 0 666; p < 0 001), and
cystatin C (R = 0 738; p < 0 001) concentrations, eGFR
calculated with Schwartz (R = −0 677; p < 0 001), and Filler
formulas (R = −0 716; p < 0 001). Scatterplot presenting the
correlation between cystatin C and thrombomodulin con-
centrations is shown in Figure 3.
Thrombomodulin concentration correlated significantly
with other endothelial dysfunction and oxidative stress
parameter concentrations: ADMA (R = 0 353; p = 0 010),
BNP (R = 0 406; p = 0 001), and oxLDL (R = 0 340; p =
0 009). Scatterplots presenting the correlations between
ADMA, BNP, oxLDL, and thrombomodulin concentra-
tions are shown in Figures 4–6. No correlation between
thrombomodulin and vWF (R = 0 239; p = 0 082), carbonyl
groups (R = 0 151; p = 0 310), hsCRP (R = 0 000; p = 0 999),
and ICAM (R = 0 082; p = 0 566) concentrations have
been found.
Thrombomodulin correlated significantly with 24-hour
systolic (R = 0 345; p = 0 011) and mean—MAP (R = 0 315;
p < 0 05) BP values. Scatterplot presenting the correlation
between mean 24-hour systolic BP values and thrombomod-
ulin concentrations is shown in Figure 7.
In the studied children with CKD, a significant correla-
tion between thrombomodulin level and LVMI was found
(R = 0 293; p = 0 024). Scatterplot presenting the correla-
tion between LVMI and thrombomodulin concentrations
is shown in Figure 8.
4. Discussion
This is, to our knowledge, the first study comparing throm-
bomodulin as endothelial dysfunction marker with oxidative
stress markers in children with chronic kidney disease.
In our study, a very strong positive correlation of the con-
centrations of thrombomodulin and urea, creatinine, and
cystatin C and a negative correlation with eGFR were
observed, which is evidence of damaging uremic effects on
endothelial cells. The highest concentrations of thrombo-
modulin were observed in dialyzed children. There were also
Table 3: Oxidative stress and endothelial dysfunction parameters depending on thrombomodulin concentration in the investigated group of
59 patients.
Parameter
Thrombomodulin
p value∗<2xULN (n = 26) ≥2xULN (n = 33)
vWF (%) 87.8 (78.8; 93.3) 90.2 (82.8; 96.7) 0.521
Carbonyl groups (nmol/mg) 1.18 (0.61; 1.89) 1.36 (0.82; 2.17) 0.634
ADMA (μmol/l) 0.94 (0.75; 1.16) 1.23 (0.90; 1.40) 0.029
BNP (pg/ml) 4.43 (1.00; 15.39) 15.63 (5.88; 24.23) 0.021
oxLDL (U/l) 80.6 (67.4; 91.9) 88.6 (78.7; 106.9) 0.033
hsCRP (ng/ml) 373.2 (132.6; 736.1) 310.7 (145.6; 878.1) 0.535
ICAM-1 (ng/ml) 373.2 (132.6; 736.1) 323.6 (290.3; 384.4) 0.977
Fibrinogen (g/l) 3.5 (2.5; 4.4) 3.3 (2.4; 4.4) 0.856
Values presented as median (25th–75th percentile). ∗Mann–Whitney U test. ULN: upper limit of normal; vWF: von Willebrand factor; ADMA: asymmetric
dimethylarginine; BNP: brain natriuretic peptide; oxLDL: oxidized low-density lipoprotein; hsCRP: high sensitive C-reactive protein; ICAM-1: intercellular
adhesion molecule-1.
Table 4: 24-hour blood pressure values depending on thrombomodulin concentration in the investigated group of 59 patients.
Parameter
Thrombomodulin
p value∗<2xULN (n = 26) ≥2xULN (n = 33)
24 h SBP (mmHg) 113.0 (105.0; 118.0) 118.0 (113.0; 126) 0.012
24 h DBP (mmHg) 65.0 (61.0; 75.0) 69.0 (62.0; 78.0) 0.063
24 h MAP (mmHg) 82.0 (77.0; 88.0) 87.0 (78.0; 92.0) 0.022
24 h SBP (SD) 0.242 (−1.408; 0.746) 0.805 (−0.875; 2.337) 0.119
24 h DBP (SD) −0.109 (−1.403; 1.375) 0.956 (−1.025; 3.511) 0.103
24 h MAP (SD) 0.309 (−0.858; 1.040) 1.472 (−0.646; 3.145) 0.076
Values presented as median (25th–75th percentile). ∗Mann–Whitney U test. ULN: upper limit of normal; SBP: systolic blood pressure; DBP: diastolic blood
pressure; MAP: mean arterial pressure.
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significantly higher renal function parameters and albumin-
uria in the group of children with thrombomodulin level
exceeding over 2 times the upper limit, but there were no
differences in cholesterol concentrations.
The CKD population is at increased risk of cardiovascu-
lar disease. Until recently, it was considered that this risk
was only increased with GFR< 60ml/min/1.73m2, but mod-
ern long-term observations indicate that the increase in
cardiovascular mortality is already present with a decrease
in GFR below 90ml/min/1.73m2 [21, 22]. In adult patients
with CKD, the cluster of CV risk factors (hypertension,
diabetes, hypercholesterolemia, and smoking) is common.
Traditional risk factors, however, cannot explain the high
prevalence of cardiovascular disease in pediatric population
with CKD, as many factors affecting ED such as diabetes,
smoking, effect of ageing, long lasting HT as a cause of
CKD, and CV comorbidities are not present in this popula-
tion, which allows for more accurate evaluation of the impact
of oxidative stress and uremia on ED.
In the studied group of children with CKD, thrombo-
modulin correlated well with BNP, a marker of myocardial
stress, and LVMI, a marker of left ventricular hypertrophy.
Accelerated atherosclerosis in patients with chronic
kidney disease is responsible for increased morbidity and
mortality due to cardiovascular causes [23]. Endothelial
dysfunction is postulated to be the pathomechanism and
early stage of atherosclerosis before the onset of clinically
manifested atherosclerotic plaques [24, 25]. Endothelial
cell function impairment also plays a role in the progres-
sion of atherosclerotic lesions and their clinical complica-
tions [26]. Cachofeiro et al. described oxidative stress,
endothelial dysfunction, and inflammation as the key triad
in the development and progression of atherosclerosis
5.00
10.00
15.00
20.00
Th
ro
m
bo
m
od
ul
in
 (n
g/
m
l)
30−300 mg/g >300 mg/g<30 mg/g
Albuminuria
Figure 1: Thrombomodulin concentrations depending on
albuminuria groups. Data are presented as median and interquartile
range.
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Figure 2: Thrombomodulin concentrations depending on
glomerular filtration rate (GFR) group. Group 1-2: CKD stages 1
+ 2 (GFR> 60); group 3: CKD stage 3 (GFR= 30–59); group 4:
CKD stage 4 (GFR= 15–29ml/min/1.73m2); group 5: dialyzed
children. Data are presented as median and intraquartile range.
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Figure 3: Scatterplot presenting the correlation between cystatin C
and thrombomodulin concentrations.
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Figure 4: Scatterplot presenting the correlation between
asymmetric dimethylarginine (ADMA) and thrombomodulin
concentrations.
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[27]. Thrombomodulin is an anticoagulant cell surface
proteoglycan that is cleaved from the endothelial cell sur-
face layer by neutrophil-derived enzymes [28, 29].
In the study by Krzanowski et al., the authors also found a
significant correlation between thrombomodulin and serum
creatinine, as well as inflammation and endothelial dysfunc-
tion markers in CKD. Adult CKD patients with severe radial
artery calcification had higher concentrations of TM than
patients with less advanced lesions. Thrombomodulin con-
centrations did not correlate with age and classical cardiovas-
cular risk factors (SCORE) which could indicate that
thrombomodulin determines vascular injury and advanced
calcification in patients with impaired renal function [30].
The role of thrombomodulin as a vasoprotective agent
may also be confirmed by the results of Eguchi et al., who
have shown that the supply of recombinant TM reverses
FK506-induced ED. Recombinant TM is registered in Japan
for DIC treatment [31].
Our study showed a significant correlation between the
marker of endothelial dysfunction and a recognized oxidative
stress marker—oxLDL. Significant increases in oxLDL levels
have been also found in children with markedly increased
thrombomodulin levels, which may indicate an intensifica-
tion of both ED and oxidative stress processes with increas-
ing renal function impairment.
Holvoet and coauthors suggested to measure the concen-
tration of circulating oxidized LDL for amore accurate assess-
ment of cardiovascular risk. Patients with coronary artery
disease confirmed in angiography had significantly higher
oxLDL levels. There was also a significant correlation between
oxLDL and most of the Framingham risk factors [32].
In the studied group, the protein carbonyl content did
not increase in the patients with higher thrombomodulin
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Figure 5: Scatterplot presenting the correlation between brain
natriuretic peptide (BNP) and thrombomodulin concentrations.
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Figure 6: Scatterplot presenting the correlation between oxidized
low-density lipoprotein (oxLDL) and thrombomodulin
concentrations.
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Figure 8: Scatterplot presenting the correlation between left
ventricular mass index (LVMI) and thrombomodulin
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levels. In our previous study, the protein carbonyl content
did not increase in advanced stages of CKD [1].
In children, there are currently no studies evaluating TM
levels in chronic kidney disease, but endothelial dysfunction
has been widely described in nephrotic syndrome. In the
study by Tkaczyk et al. and Sharma et al., children with active
disease had significantly higher thrombomodulin concentra-
tions compared to control group [33, 34].
In the studied group of children with chronic kidney dis-
ease, thrombomodulin correlated significantly with another
mediator of endothelial injury—ADMA. ADMA meets mul-
tiple uremic toxin criteria—it is a product of protein metab-
olism, is accumulating in renal failure, is removed during
dialysis, and has a specific mechanism of action. In kidney
disease, not only ADMA excretion in the urine but also its
metabolism (by enzymatic decomposition—dimethylargi-
nine dimethylaminohydrolase) in kidney tissue is reduced.
In the group of 600 patients with long-term type 1 diabe-
tes (mean duration of 28 years), statistically significant differ-
ences in ADMA between patients with diabetic nephropathy
and normoalbuminuria (0.46 versus 0.4μmol/l) were found
[35]. ADMA concentration was also significantly higher in
patients with nephropathy and history of stroke or myocar-
dial infarction compared to patients without cardiovascular
events (0.48 versus 0.46μmol/l). The authors emphasized
the fact that ADMA increased in the early stage of diabetic
renal disease, that is, at GFR< 76ml/min/1.73m2.
In the study by Kielstein and coworkers, ADMA was ele-
vated at an early stage of renal failure [36]. Further research is
needed to clarify whether elevated ADMA levels in patients
with CKD are markers of renal failure or cardiovascular
disease mediators [37]. The Zoccali group demonstrated a
relationship between ADMA concentration and intima-
media thickness in hemodialysis patients. There was also a
strong relation between inflammation (CRP), endothelial
dysfunction markers (ADMA), and the effect of these factors
on the progression of vascular changes in patients with base-
line normal IMT [38].
In the group of children with thrombomodulin level
exceeding over 2 times the upper limit, significantly higher
ADMA levels have been found.
In the studied children with higher thrombomodulin
concentrations, significantly higher albuminuria has been
found. Albuminuria is another indicator of endothelial
injury. The relationship between renal albumin loss and car-
diovascular risk in different groups of patients with increased
vascular damage (hypertension, diabetes) has been demon-
strated. Albuminuria is a recognized cardiovascular risk fac-
tor and an indicator of renal failure [39]. In the RENAAL
study in subjects with type 2 diabetes, reduction of albumin-
uria during 6 months of losartan treatment was the strongest
factor of cardiovascular protection [40]. An increase in albu-
minuria by 1 g/g of creatinine in the baseline examination
was associated with a 17% increase of cardiovascular end-
point risk and a 26% higher risk of developing heart failure.
The Heart Outcome Prevention Evaluation (HOPE) study
has shown that even a slight degree of albuminuria increases
the risk of cardiovascular events. Each increase in urinary
albumin to creatinine ratio by 0.4mg/mmol increased risk
by 5.9% [41]. The association between albuminuria and mor-
tality was also demonstrated in a population of healthy indi-
viduals without diabetes and hypertension [42].
The acquired results—significantly higher systolic and
mean blood pressure values in patients with higher thrombo-
modulin levels—prove the well-known influence of hyper-
tension on endothelial damage.
Endothelial dysfunction has been proposed as one of the
main mechanisms contributing to the association of chronic
kidney and cardiovascular disease. In CKD oxidative stress,
subclinical chronic inflammation and uremic toxins are
responsible for endothelial cell injury [43]. The potential
pathomechanism of increased shedding of TM is the
increased cyclic strain caused by hypertension [6].
The lack of correlation between TM and other ED bio-
markers (vWF, ICAM-1, and fibrinogen) may be the result
of the small study group.
5. Conclusions
In children with chronic kidney disease, thrombomodulin
seems to be a valuable marker of endothelial dysfunction,
correlating strongly with CKD stage, kidney function param-
eters (urea, creatinine, and cystatin C), as well as oxidative
stress, hypertension, and left ventricular hypertrophy.
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